Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danny Bega

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Journal of Neurology, Neurosurgery, and Psychiatry|July 13, 2019
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesiaHubert H Fernandez, David Stamler, Mat D Davis, et al.
Journal of Palliative Medicine|January 6, 2023
Death Anxiety in Huntington Disease: Longitudinal Heath-Related Quality-of-Life OutcomesLeonard L Sokol, Jonathan P Troost, Danny Bega, et al.
Movement Disorders Clinical Practice|April 11, 2017
Impact of Depression on Progression of Impairment and Disability in Early Parkinson's DiseaseDanny Bega, Sheng Luo, Hubert Fernandez, et al.
Neurology|April 28, 2017
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD studyHubert H Fernandez, Stewart A Factor, Robert A Hauser, et al.
Frontiers in Neurology|July 19, 2021
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of CareBrent Bluett, Alexander Y Pantelyat, Irene Litvan, et al.
Journal of Clinical Medicine|November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical TrialMichael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Journal of Neurology, Neurosurgery, and Psychiatry|July 13, 2019
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesiaHubert H Fernandez, David Stamler, Mat D Davis, et al.
Journal of Palliative Medicine|January 6, 2023
Death Anxiety in Huntington Disease: Longitudinal Heath-Related Quality-of-Life OutcomesLeonard L Sokol, Jonathan P Troost, Danny Bega, et al.
Movement Disorders Clinical Practice|April 11, 2017
Impact of Depression on Progression of Impairment and Disability in Early Parkinson's DiseaseDanny Bega, Sheng Luo, Hubert Fernandez, et al.
Neurology|April 28, 2017
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD studyHubert H Fernandez, Stewart A Factor, Robert A Hauser, et al.
Frontiers in Neurology|July 19, 2021
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of CareBrent Bluett, Alexander Y Pantelyat, Irene Litvan, et al.
Journal of Clinical Medicine|November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical TrialMichael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Pageof 6